Premature babies and pharmacology.
Where this comes from
- Record sourced from PubMed, PMID 8529189.
- Also identified by PMC identifier PMC1488195.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In his research on the action of various drugs in newborns, Dr. Jacob Aranda of the Centre for Perinatal and Developmental Pharmacology Research in Montreal draws upon his expertise in both neonatology and pharmacology. His work has led to the acceptance of caffeine as a standard treatment of apnea in premature infants, and his current studies of ibuprofen as a possible treatment of cerebral intraventricular hemorrhage, a serious problem in some premature babies, have yielded promising results. Other areas being tackled by Aranda and his colleagues include pain control for newborns and the elusive pathology of sudden infant death syndrome. By shedding more light on neonatal development and the principles of drug action in newborns, these research projects will help to improve the odds for many babies who suffer the setback of being born too soon.